Of relevance is the observation that the same mechanism described in CML cell lines is active in leukocytes from CML patients, where PTPRG inhibition results in the up-regulation of Y245-phospho-BCR-ABL1 and Y654-phospho-β-catenin. Here, PTPRG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.